Policy analysis on the regulation of the medicinal use of products derived from Cannabis spp. in Brazil (2014-2021)

• Autor(a) principal: Araujo, Patricia Sodré
• Data de Publicação: 2022
• Outros Autores: Costa, Ediná Alves, Sandes, Carla Freitas Benamor, Cruz, Emylle Cardoso Dias da, Rocha, Juliana Santos, Soares, Laíse Caroline Costa, Pereira, Marcelo Tavares
• Tipo de documento: Artigo
• Idioma: por; eng
• Título da fonte: Vigilância Sanitária em Debate
• Texto Completo: https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/2043
• topic: Maconha Medicinal; Regulação Governamental; Vigilância Sanitária; Medicamentos; regulação economica; regulação de medicamentos; Medical Marijuana; Government Regulation; Health Surveillance; Marihuana Medicinal; Regulación Gubernamental; Vigilancia Sanitaria

Introduction: The medicinal use of Cannabis derivatives divides opinions in civil society. However, for many patients who need treatment, the regulation of the importation and use of these products represents hope and quality of life. Objective: To identify the main facts and positions related to the regulation of medicinal products based on Cannabis from 2014 to 2021 by Anvisa, the Ministry of Health, the Chamber of Deputies and the Federal Councils of Pharmacy and Medicine. Method: This is a case study resulting from the analysis of the facts and positions identified by different actors, selected considering a time frame from 2014 to 2021. The production of data included sources from the Thematic Axis database Medicines, Blood, Pharmaceutical Assistance and Health Surveillance Policies, developed in partnership with researchers from the State University of Bahia, which is part of the Observatory of Policy Analysis in Health of the Collective Health Institute of the Federal University of Bahia. Results: Several countries, such as Argentina, Mexico, Thailand, Canada, Israel, and several states in the USA, have changed their legislation so that it is possible to expand the use of Cannabis-based drugs. In Brazil however, this is a long process, which involves several divergences and positions of different political actors. Conclusions: The topic is relevant; discussions and debates allow society to be informed about how the government is conducting the regulation to allow the production of Cannabis-based medicines as a therapeutic alternative for conditions that do not yet have drug therapies.